ADC Therapeutics
ADCT
59 hedge funds and large institutions have $801M invested in ADC Therapeutics in 2021 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 17 increasing their positions, 12 reducing their positions, and 12 closing their positions.
274% more call options, than puts
Call options by funds: $8.9M | Put options by funds: $2.38M
67% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 12
42% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 12
16% more funds holding
Funds holding: 51 → 59 (+8)
1.6% more ownership
Funds ownership: 41.19% → 42.79% (+1.6%)
21% less capital invested
Capital invested by funds: $1.01B → $801M (-$210M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
+$24M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$22.6M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
+$15.9M |
| 4 |
MICM
Matthews International Capital Management
San Francisco,
California
|
+$10.7M |
| 5 |
JP Morgan Chase
New York
|
+$4.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$21.9M |
| 2 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$9.32M |
| 3 |
WG
Winton Group
London,
United Kingdom
|
-$5.3M |
| 4 |
BlackRock
New York
|
-$5.28M |
| 5 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$5.06M |
ADCT Hedge Fund Activity: Q1 2021 in Review
59 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in ADC Therapeutics (ADCT) for Q1 2021, worth a combined $801M — down 21% from $1.01B a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new ADCT positions and 12 closed out — a net gain of 8 holders — while 17 added to existing stakes and 12 trimmed.
The largest buyer was AllianceBernstein, adding an estimated $24M. The largest seller was Polar Capital Holdings, exiting entirely with an estimated $21.9M sold.
- 59 institutional investors held ADC Therapeutics (ADCT) as of Q1 2021, up from 51 in Q4 2020.
- Funds reported $801M of ADC Therapeutics stock for Q1 2021, down 21% quarter-over-quarter.
- 20 funds opened new ADC Therapeutics positions in Q1 2021 and 12 closed out, a net change of +8 holders.
- The largest ADC Therapeutics buyer in Q1 2021 was AllianceBernstein, an estimated $24M added.
- The largest ADC Therapeutics seller in Q1 2021 was Polar Capital Holdings, an estimated $21.9M sold.
Based on aggregated 13F filings for Q1 2021.